News

Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or the “Company”), a small molecule…

2 years ago

Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced…

2 years ago

Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative…

2 years ago

CloudMD Appoints Karen Adams as Chief Executive Officer and John Plunkett as Chief Financial Officer

VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH)…

2 years ago

CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc.…

2 years ago

Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing a 13% Increase Over the Prior Year

31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the prior year#12 ranking for market…

2 years ago

Quipt Home Medical to Participate at the Sidoti Virtual Investor Conference on August 17th – 18th

WEBCASTED PRESENTATION TO BE HELD WEDNESDAY, AUGUST 17THCINCINNATI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company” or “Quipt”)…

2 years ago

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid…

2 years ago

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva…

2 years ago

Lucira Announces Health Canada Authorization of First and Only 99% Accurate At-Home Covid & Flu Test

Lucira COVID-19 & Flu Test – the 99% Accurate At-Home Test for Covid and Flu The first and only at-home…

2 years ago